SCHEMBL7003853

SCHEMBL7003853

CCOC(=O)n1cc(-n2c(-c3c[nH]c4ccc(OC)cc34)c[nH]c2=O)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.42
HTR1A P08908 2/20 0.41
HTR7 P34969 1/20 0.41
HTR6 P50406 1/20 0.41
PRKD1 Q15139 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PDE4B Q07343 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
DRD4 P21917 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MITF O75030 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7008320 0.89 RPS6KB1 (0.41) CAMK2DPRKD1TDP1MAPTMEN1
SCHEMBL7008865 0.80 PIM1 (0.40) CAMK2DLMNAPOLB
SCHEMBL7006065 0.77 PKM (0.39) CAMK2DPRKD1TDP1MAPTMEN1
SCHEMBL7009411 0.74 ALDH1A1 (0.41) CAMK2DMAPTMEN1KMT2ANPSR1
SCHEMBL7010209 0.71 PIM1 (0.37) CAMK2DPRKD1TDP1MAPTMEN1
SCHEMBL18392213 0.65 CAMK2D (0.53) CAMK2DPDE4BGPR84MAPTMEN1
SCHEMBL7010672 0.64 SIRT2 (0.48) CAMK2DHTR1AHTR7HTR6PRKD1
SCHEMBL2866771 0.64 NR4A2 (0.74) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL31451717 0.64 NR4A2 (0.74) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL18392204 0.64 ABCG2 (0.57) PDE4BGPR84MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 EP claimed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 US claimed
US-20030134886-A1 Pharmaceutically active compounds ASTRAZENECA AB, A SWEDISH CORPORATION 2003-07-17 US disclosed
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-6492409-B1 SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-10 US disclosed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134886-A1 Pharmaceutically active compounds HTR3C, HTR6, CNR1 CAMK2D 3573/4885HTR1A 5/4885HTR7 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.